A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood

Clinical Cancer Research

Volumn 3, Issue 7, 1997, Pages 1109-1115

  Pollack, Ian F ^a   Darosso, Robert C ^b   Robertson, Patricia L ^c   Jakacki, Regina L ^d   Mirro Jr , Joseph R ^a   Blatt, Julie ^a   Nicholson, Stacy ^e   Packer, Roger J ^e   Allen, Jeffrey C ^b   Cisneros, Angela ^f   Jordan, V Craig ^f  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d School of Medicine ^*  (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; NAVELBINE; PROCARBAZINE; TAMOXIFEN; VINCRISTINE;

ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; FEMALE; GLIOMA; HUMAN; LONG QT SYNDROME; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; MALE; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS;

EID: 0030808172     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pollack, I. F. Current concepts: brain tumors in children. New Engl. J. Med., 331: 1500-1507, 1994.
2. Sposto, R., Ertel, I. J., Jenkin, R. D., Boesel, C. P., Venes, J. L., Ortega, J. A., Evans, A. E., Wara, W., and Hammond, D. The effectiveness of chemotherapy for treatment of high-grade astrocytoma in children: results of a randomized trial. J. Neuro-oncol., 7: 165-177, 1989.
3. Finlay, J. L., Boyett, J. M., Yates, A. J., Wisoff, J. H., Milstein, J. M., Geyer, J. R., Bertolone, S. J., McGuire, P., Cherlow, J. M., Tefft, M., Turski, P. A., Wara, W. M., Edwards, M., Sutton, L. N., Berger, M. S., Epstein, F., Ayers, G., Allen, J. C., and Packer, R. J. for the Children's Cancer Group. Randomized Phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J. Clin. Oncol., 13: 112-123, 1995.
4. Campbell, J., Pollack, I. F., Shultz, B. L., and Martinez A. J. Prognostic factors in the management of pediatric malignant gliomas. Neurosurgery (Baltimore), 38: 258-264, 1996.
5. Packer, R. J., Boyett, J. M., Zimmerman, R. A., Rorke, L. B., Kaplan, A. M., Albright, A. L., Selch, M. T., Finlay, J. L., Hammond, G. D., and Wara, W. M. Hyperfractionated radiotherapy (7200 cGy) tor children with brain stem gliomas: a Children's Cancer Group Phase I/II trial. Cancer (Phila.), 72: 1414-1421, 1993.
6. Jennings, M. T., Freeman, M. L., and Murray, M. J. Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy. J. Neuro-oncol., 28: 207-222, 1996.
7. Packer, R. J. Brain stem gliomas: therapeutic options at time of recurrence. Pediatr. Neurosurg., 24: 211-216, 1996.
8. Pollack, I. F., Randall, M. S., Kristofik, M. P., Kelly, R. H., Selker, R. G., and Vertosick, F. T., Jr. Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways. J. Neurosurg., 73: 98-105, 1990.
9. Pollack, I. F., Randall M. S., Kristofik, M. P., Kelly, R. H., Selker, R. G., and Vertosick, F. T., Jr. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res., 50: 7134-7138, 1990.
10. Pollack, I. F., Kawecki, S., and Lazo, J. S. 7-Hydroxystaurosporine (UCN-01), a selective protein kinase C inhibitor, exhibits cytotoxicity against cultured glioma cells and potentiates the antiproliferative effects of BCNU and cisplatin. J. Neurosurg., 84: 1024-1032, 1996.
11. Couldwell, W. T., Uhm, J. H., Antel, J. P., and Yong, V. W. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery (Baltimore), 29: 880-887, 1991.
12. Couldwell, W. T., Antel, J. P., and Yong, V. W. Protein kinase C activity correlates with the growth rate of malignant gliomas. II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery (Baltimore), 31: 717-724, 1992.
13. Baltuch, G. H., Couldwell, W. T., Villemure, J-G., and Yong, V. W. Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines: a comparison between staurosporine and tamoxifen. Neurosurgery (Baltimore), 33: 495-501, 1993.
14. Ahmad, S., Mineta, T., Martuza, R. L., and Glazer, R. I. Antisense expression of protein kinase C α inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery (Baltimore), 35: 904-909, 1994.
15. Vertosick, F. T., Selker, R. G., Randall, M. S., Kristofik, M. P., and Rehn, T. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and N-desmethyltamoxifen in vitro. J. Neurooncol., 19: 97-103, 1994.
16. O'Brian, C. A., Liskamp, R. M., Solomon, D. H., and Weinstein, I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res., 45: 2452-2465, 1985.
17. Horgan, K., Cooke, E., Hallett, M. B., and Mansel, R. E. Inhibition of protein kinase C mediated signal transduction by tamoxifen: importance for antitumor activity. Biochem. Pharmacol., 35: 4463-4465, 1986.
18. Baum, M., Brinkley, D. M., Dosset, J. A., McPherson, K., Jackson, I. M., Rubens, R. D., Smiddy, F. G., Stoll, B. A., Wilson, A. J., Birch, I. H., and Palmer, M. K. Controlled trial of tamoxifen as a single agent in the management of early breast cancer: analysis at eight years by "Nolvadex" Adjuvant Trial Organization. Br. J. Cancer, 57: 608-611, 1988.
19. Bianco, A. G., DePlacido, S., and Gallo, C. Adjuvant therapy with tamoxifen in operable breast cancer: 10 year results of the Naples (GUN) study. Lancet, 2: 1095-1096, 1988.
20. Fornander, T., Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J., et al. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J. Clin. Oncol., 9: 1740-1748, 1991.
21. Vertosick, F. T., Jr., Selker, R. G., Pollack, I. F., and Arena, V. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. Neurosurgery (Baltimore), 30: 897-903, 1992.
22. Couldwell, W. T., Weiss, M. H., DeGiorgio, C. M., Weiner, L. P., Hinton, D. R., Ehresmann, G. R., Conti, P. S., and Apuzzo, M. L. J. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery (Baltimore), 32: 485-490, 1993.
23. Vertosick, F. T., Jr., Selker, R. G., and Arena, V. A dose-escalation study of tamoxifen therapy in patients with recurrent glioblastoma multiforme. J. Neurosurg., 80: 385A, 1994.
24. Preul, M. C., Caramanos, Z., Shenouda, G., Langleben, A., Villemure, J-G., Leblanc, R. A., Olivier, A., Tampieri, D., Bahary, J. P., and Arnold, D. L. In vivo biochemical effects of tamoxifen on recurrent malignant astrocytomas: characteristics of response and failure. J. Neurosurg., 84: 352A-353A, 1996.
25. Baltuch, G. H., Shenouda, G., Langleben, A., and Villemure J-G. High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression. Can. J. Neurol. Sci., 20: 168-170, 1993.
26. Pollack, I. F., Kawecki, S. The efficacy of tamoxiten as an anti-proliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatr. Neurosurg., 22: 281-288, 1995.
27. Trump, D. L., Smith, D. C., Ellis, P. G., Rogers, M. P., Schold, S. C. Winer, E. P., Panella, T. J., Jordan, V. C., and Fine, R. L. High dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J. Natl. Cancer Inst., 84: 1811-1816, 1992.
28. Lansky, L., List, M., Lansky, S., Cohen, M., and Sinks, L. Towards the development of a play performance scale for children. Cancer (Phila.), 56: 1837-1840, 1985.
29. Fried, K. M., and Wainer, I. W. Direct determination of tamoxiten and its four major metabolites in plasma using coupled column high performance liquid chromatoaraphy. J. Chromatogr. B, 655: 261-268, 1994.
30. Basu, A., and Lazo, J. S. Protein kinase C. In: D. J. Kerr and P. Workman P (eds.), New Molecular Targets for Cancer Chemotherapy, pp. 121-141. Boca Raton, FL: CRC Press, Inc., 1994.
31. Hait, W. M., and Lazo, J. S. Calmodulin: a potential target for cancer chemotherapeutic agents. J. Clin. Oncol., 4: 994-1012, 1986.
32. Lien, E. A., Solheim, E., and Ueland, P. M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 51: 4837-4844, 1991.
33. Lien, E. A., Solheim, E., Lea, O. A., Lundgren, S., Kvinnsland, S., and Ueland, P. M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res., 49: 2175-2183, 1989.
34. Fahey, S. M. L., Jordan, V. C., Fritz, N. F., Robinson, S. P., Waters, D., and Tormey, D. C. Clinical pharmacology and endocrinology of long-term tamoxifen therapy. In: V. C. Jordan (ed.), Long-Term Tamoxifen Treatment for Breast Cancer, pp. 27-56. Madison, WI: University of Wisconsin Press, 1994.
35. Stuart, N. S. A., Philip, P., Harris, A. L., Tonkin, K., Houlbrook, S., Kirk, J., Lien, E. A., and Carmichael, J. High-dose tamoxifen as an enhancer of etoposide cytotoxicity: clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br. J. Cancer, 66: 833-839, 1992.
36. Millward, M. J., Cantwell, B. M. J., Lien, E. A., Carmichael, J., and Harris, A. L. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur. J. Cancer, 28A: 805-810, 1992.
37. Lien, E. A., Wester, K., Lonning, P. E., Solheim, E., and Ueland, P. M. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer. 63: 641-645, 1991.
38. Freeman, A., Hetheringlon, M., Egelhoff, J., Hanson, E. J., Pons, M., Massey, V., Zwick, D., and Convy, L. Preliminary results: diffuse intrinsic brain stem gliomas of childhood respond to tamoxifen. Proc. Am. Assoc. Cancer Res., 35: 470, 1994.
39. Fine, R. L., Williams, A., Jett, C. R., Jordan, V. C., and Trump, D. L. Tamoxifen potentiates the antitumor effect of vinblastine against intrinsically multidrug resistant (mdr) human renal carcinoma cell lines (RCC). Proc. Am. Assoc. Cancer Res., 31: 359, 1990.
40. McClay, E. F., Albright, K. D., Jones, J. A., Christen, R. D., and Howell, S. B. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res., 53: 1571-1576, 1993.